摘要
We congratulate Simon J Bowman and colleagues1Bowman SJ Fox R Dörner T et al.Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.Lancet. 2022; 399: 161-171Summary Full Text Full Text PDF PubMed Scopus (18) Google Scholar on the success of ianalumab in primary Sjögren's syndrome, particularly after the paucity of successful phase 2 randomised controlled trials in the condition. This trial showed an improvement in disease activity (ie, the European League Against Rheumatism [EULAR] Sjögren's Syndrome Disease Activity Index score), whereas symptom burden and health-related quality of life (ie, the EULAR Sjögren's Syndrome Patient Reported Index, the Functional Assessment of Chronic Illness Therapy-Fatigue, short form 36, and the Patient Global Assessement scale) did not show significant improvement compared with placebo. The disconnect between patient-reported and physician-reported outcomes highlights challenges in trial design that need to be considered when progressing to phase 3 trials. We note attempts in the ongoing TWINSS study to separate patients into two subgroups to finesse the phase 3 trial design (NCT03905525).Systemic lupus erythematosus and primary Sjögren's syndrome share a history of clinical trials not reaching their primary endpoint. Our personal experience of and published evidence from previous systemic lupus erythematosus trials shows that therapies often show promise in phase 2 trials that does not usually translate to success in phase 3. Not meeting the majority of the phase 2 endpoints might serve as a particular warning of the risk of therapies not working at phase 3. For example, the phase 2b trial2Wallace DJ Kalunian K Petri MA et al.Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.Ann Rheum Dis. 2014; 73: 183-190Crossref PubMed Scopus (217) Google Scholar of epratuzumab showed improvements in the British Isles Lupus Assessment Group-based Composite Lupus Assessment but not in the Systemic Lupus Erythematosus Disease Activity Index (version 2K), mean corticosteroid use, and the Physician's Global Assessment, but then did not achieve the primary endpoint in two phase 3 trials. In contrast, anifrolumab met the several composite (ie, Systemic Lupus Erythematosus Responder Index-4 and the British Isles Lupus Assessment Group-based Composite Lupus Assessment) and organ-specific domains (ie, Cutaneous Lupus Erythematosus Disease Area and Severity Index activity and joint counts) in a phase 2b trial3Furie R Khamashta M Merrill JT et al.Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.Arthritis Rheumatol. 2017; 69: 376-386Crossref PubMed Scopus (460) Google Scholar and went on to have success in phase 3 trials, which led to its regulatory approval for moderate-to-severe systemic lupus erythematosus.4Morand EF Furie R Tanaka Y et al.Trial of anifrolumab in active systemic lupus erythematosus.N Engl J Med. 2020; 382: 211-221Crossref PubMed Scopus (386) Google Scholar, 5Furie RA Morand EF Bruce IN et al.Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.Lancet Rheumatol. 2019; 1: e208-e219Summary Full Text Full Text PDF Scopus (150) Google ScholarWith ianalumab, we suggest that careful analysis of the effect of comorbidities (eg, fibromyalgia), pre-existing damage, and study design should be examined further, and such lessons factored into the design of the phase 3 programme.SD received grant support from UCB and Eli Lilly. INB received grant support from Genzyme/Sanofi, GSK, Roche, and UCB; consulting fees from AstraZeneca, Eli Lilly, GSK, Merck Serono, and UCB; and was a speaker for AstraZeneca, GSK, and UCB. BP received grant support from Genzyme/Sanofi and GSK; honoraria from Fresenius-Kabi and AbbVie; and was a speaker for Eli Lilly and Roche. We congratulate Simon J Bowman and colleagues1Bowman SJ Fox R Dörner T et al.Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.Lancet. 2022; 399: 161-171Summary Full Text Full Text PDF PubMed Scopus (18) Google Scholar on the success of ianalumab in primary Sjögren's syndrome, particularly after the paucity of successful phase 2 randomised controlled trials in the condition. This trial showed an improvement in disease activity (ie, the European League Against Rheumatism [EULAR] Sjögren's Syndrome Disease Activity Index score), whereas symptom burden and health-related quality of life (ie, the EULAR Sjögren's Syndrome Patient Reported Index, the Functional Assessment of Chronic Illness Therapy-Fatigue, short form 36, and the Patient Global Assessement scale) did not show significant improvement compared with placebo. The disconnect between patient-reported and physician-reported outcomes highlights challenges in trial design that need to be considered when progressing to phase 3 trials. We note attempts in the ongoing TWINSS study to separate patients into two subgroups to finesse the phase 3 trial design (NCT03905525). Systemic lupus erythematosus and primary Sjögren's syndrome share a history of clinical trials not reaching their primary endpoint. Our personal experience of and published evidence from previous systemic lupus erythematosus trials shows that therapies often show promise in phase 2 trials that does not usually translate to success in phase 3. Not meeting the majority of the phase 2 endpoints might serve as a particular warning of the risk of therapies not working at phase 3. For example, the phase 2b trial2Wallace DJ Kalunian K Petri MA et al.Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.Ann Rheum Dis. 2014; 73: 183-190Crossref PubMed Scopus (217) Google Scholar of epratuzumab showed improvements in the British Isles Lupus Assessment Group-based Composite Lupus Assessment but not in the Systemic Lupus Erythematosus Disease Activity Index (version 2K), mean corticosteroid use, and the Physician's Global Assessment, but then did not achieve the primary endpoint in two phase 3 trials. In contrast, anifrolumab met the several composite (ie, Systemic Lupus Erythematosus Responder Index-4 and the British Isles Lupus Assessment Group-based Composite Lupus Assessment) and organ-specific domains (ie, Cutaneous Lupus Erythematosus Disease Area and Severity Index activity and joint counts) in a phase 2b trial3Furie R Khamashta M Merrill JT et al.Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.Arthritis Rheumatol. 2017; 69: 376-386Crossref PubMed Scopus (460) Google Scholar and went on to have success in phase 3 trials, which led to its regulatory approval for moderate-to-severe systemic lupus erythematosus.4Morand EF Furie R Tanaka Y et al.Trial of anifrolumab in active systemic lupus erythematosus.N Engl J Med. 2020; 382: 211-221Crossref PubMed Scopus (386) Google Scholar, 5Furie RA Morand EF Bruce IN et al.Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.Lancet Rheumatol. 2019; 1: e208-e219Summary Full Text Full Text PDF Scopus (150) Google Scholar With ianalumab, we suggest that careful analysis of the effect of comorbidities (eg, fibromyalgia), pre-existing damage, and study design should be examined further, and such lessons factored into the design of the phase 3 programme. SD received grant support from UCB and Eli Lilly. INB received grant support from Genzyme/Sanofi, GSK, Roche, and UCB; consulting fees from AstraZeneca, Eli Lilly, GSK, Merck Serono, and UCB; and was a speaker for AstraZeneca, GSK, and UCB. BP received grant support from Genzyme/Sanofi and GSK; honoraria from Fresenius-Kabi and AbbVie; and was a speaker for Eli Lilly and Roche.